Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesSernova Corp

Sernova Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.08 USD 0.00(0%)
Last update at 2026-11-05T21:00:00Z
VOLUME
20000
Market Cap
28.66M

Momentum Score

…

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.08
Low
0.09
High
52 Week Price Range
0.07
Low
0.14
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Sernova Corporation is a clinical-stage company developing the Cell Pouch System, an implanted, vascularized device designed to host therapeutic cells for chronic conditions such as insulin-dependent diabetes. Major long-term growth drivers include clinical trial progress and regulatory approvals, licensing or partnerships to commercialize the platform, and the ability to scale cell manufacturing and distribution. Investors may find the company attractive because the platform could support multiple cell therapies addressing large unmet needs in metabolic and endocrine diseases.

The most important investment risks are high clinical and regulatory uncertainty, substantial financing and execution requirements to complete development and scale manufacturing, competitive alternative cell-therapy approaches and diabetes treatments, and limited liquidity and disclosure typical of a small-cap OTC-listed firm.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.08
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-726.29%
Net Debt
4.51M
ROCE
62.51%
Diluted EPS TTM
-0.03

Insight Announcement

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Income before tax -15.73M -32.19M -39.00M -24.42M -6.97M
Net income -15.74M -32.19M -39.00M -24.42M -6.97M
Selling general administrative 7.50M 8.94M 8.43M 7.83M 2.29M
Reconciled depreciation 0.34M 0.54M 0.45M 0.44M 0.27M
Ebit - - - -24.75M -6.94M
Ebitda - - - -23.86M -6.64M
Operating income -15.02M -31.66M -40.50M -24.75M -6.94M
Interest expense 0.75M 0.59M 0.03M 0.12M 0.06M
Tax provision 0.01M 0.01M 0.00M - -
Interest income 0.03M 0.39M 1.50M 0.58M 0.07M
Net interest income -0.73M -0.20M 1.47M 0.46M 0.01M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 15.02M 31.66M 40.50M 24.75M 6.94M
Total other income expense net 0.02M -0.32M 0.04M -0.13M -0.04M
Net income from continuing ops -15.74M -32.19M -39.00M -24.42M -6.97M
Net income applicable to common shares - - - -24.42M -6.97M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Total assets 0.76M 7.53M 22.11M 52.48M 29.82M
Intangible assets - - - 0.52M 0.72M
Other current assets 0.14M 0.16M 0.16M - -
Total liab 25.84M 20.48M 9.59M 4.88M 1.75M
Total stockholder equity -25.08M -12.96M 12.51M 47.61M 28.07M
Other current liab 3.73M - - - 0.07M
Common stock - - - 110.99M 74.01M
Capital stock 118.70M 116.68M 110.99M 110.99M 74.01M
Retained earnings -166.10M -150.36M -118.17M -79.17M -54.75M
Other assets - - - 0.22M 0.21M
Cash 0.27M 6.01M 8.72M 3.78M 27.87M
Total current liabilities 24.80M 20.02M 9.59M 4.74M 1.48M
Net debt 4.51M - - - -
Short long term debt 3.73M - - - -
Other stockholder equity - - - 3.30M 3.69M
Property plant equipment - - - 0.65M 0.56M
Total current assets 0.52M 6.47M 21.02M 51.09M 28.33M
Net tangible assets - - - 47.09M 27.35M
Short term investments - 0.00M 11.08M 46.00M -
Net receivables - - - 1.15M 0.45M
Long term debt 1.04M - - - -
Accounts payable 5.16M 17.24M 6.85M 3.61M 0.38M
Non currrent assets other - - - - 0.39M
Non current assets total 0.24M 1.06M 1.08M 1.39M 1.49M
Capital lease obligations 0.00M 0.57M 0.14M 0.28M 0.39M
Breakdown 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Type yearly yearly yearly yearly yearly
Date 2025-10-31 2024-10-31 2023-10-31 2022-10-31 2021-10-31
Investments 0.00M 11.08M 34.78M -46.00M -46.00M
Change to liabilities - - - 3.31M 0.46M
Total cashflows from investing activities - - - -46.34M -0.23M
Net borrowings 4.82M -0.17M -0.17M -0.17M -0.03M
Total cash from financing activities 5.14M 5.07M 0.50M 36.66M 31.00M
Change to operating activities - - - -0.16M 0.14M
Net income -15.74M -32.19M -39.00M -24.42M -6.97M
Change in cash -5.75M -2.71M 4.95M -24.10M 23.92M
Begin period cash flow 6.01M 8.72M 3.78M 27.87M 3.95M
End period cash flow 0.27M 6.01M 8.72M 3.78M 27.87M
Total cash from operating activities -10.91M -18.90M -30.34M -14.42M -6.84M
Issuance of capital stock 0.25M 4.96M 0.00M 20.28M 21.13M
Depreciation 0.34M 0.54M 0.45M 0.44M 0.27M
Other cashflows from investing activities - - - -0.01M -0.21M
Change to account receivables - - - -0.20M -0.09M
Other cashflows from financing activities - - - 0.28M 3.47M
Change to netincome - - - 6.61M -0.66M
Capital expenditures 0.00M 0.00M 0.10M 0.33M 0.02M
Change in working capital 1.74M 11.16M 4.99M 2.95M 0.52M
Stock based compensation 2.30M 1.75M 3.90M 7.45M 0.22M
Other non cash items 0.52M -0.15M -0.68M -0.84M -0.88M
Free cash flow -10.91M -18.90M -30.44M -14.75M -6.86M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
SEOVF
Sernova Corp		 -
-%		 0.08 - - - 24.48 -13.97
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Sernova Corp

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc is based in Mississauga, Canada.

RPO Central Parkway, Mississauga, ON, Canada, L5A 4H2

917-751-5713

https://www.sernova.com

8

Name Title Year Born
Mr. Frank A. Holler MBA Exec. Chairman 1957
Dr. Philip M. Toleikis B.A., M.Sc., Ph.D. Pres, CEO & Director NA
Mr. David Swetlow C.A, C.A., CPA Chief Financial Officer NA
Mr. Douglas Maret Chief Science Officer NA
Mr. Christopher Barnes VP of Investor Relations NA
Mr. Jonathan M. N. Rigby M.B.A. President, CEO & Director 1968
Mr. James T. Parsons CPA-CA, MAcc Chief Financial Officer 1965
Ms. Marylyn Rigby Chief Communications Officer NA
Dr. Pericles Calias Ph.D. Chief Development Officer and Head of R&D 1968
Mr. David Burke Vice President of Investor Relations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…